Arrowhead Pharmaceuticals, Inc. (ARWR)
86.34
-0.15
(-0.17%)
USD |
NASDAQ |
Sep 04, 16:00
86.95
+0.61
(+0.71%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Research and Development Expense (Quarterly) : 192.06M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 192.06M |
| March 31, 2026 | 167.38M |
| December 31, 2025 | 171.32M |
| September 30, 2025 | 168.80M |
| June 30, 2025 | 156.65M |
| March 31, 2025 | 127.53M |
| December 31, 2024 | 132.28M |
| September 30, 2024 | 131.39M |
| June 30, 2024 | 148.16M |
| March 31, 2024 | 97.02M |
| December 31, 2023 | 112.64M |
| September 30, 2023 | 96.40M |
| June 30, 2023 | 91.89M |
| March 31, 2023 | 72.62M |
| December 31, 2022 | 81.41M |
| September 30, 2022 | 81.12M |
| June 30, 2022 | 69.98M |
| March 31, 2022 | 73.80M |
| December 31, 2021 | 63.60M |
| September 30, 2021 | 63.28M |
| June 30, 2021 | 57.90M |
| March 31, 2021 | 42.95M |
| December 31, 2020 | 34.88M |
| September 30, 2020 | 41.87M |
| June 30, 2020 | 31.19M |
| Date | Value |
|---|---|
| March 31, 2020 | 28.22M |
| December 31, 2019 | 22.26M |
| September 30, 2019 | 22.31M |
| June 30, 2019 | 18.29M |
| March 31, 2019 | 19.63M |
| December 31, 2018 | 16.40M |
| September 30, 2018 | 14.77M |
| June 30, 2018 | 10.88M |
| March 31, 2018 | 10.86M |
| December 31, 2017 | 8.432M |
| September 30, 2017 | 8.280M |
| June 30, 2017 | 6.906M |
| March 31, 2017 | 6.977M |
| December 31, 2016 | 9.527M |
| September 30, 2016 | 11.67M |
| June 30, 2016 | 9.423M |
| March 31, 2016 | 10.02M |
| December 31, 2015 | 10.34M |
| September 30, 2015 | 10.39M |
| June 30, 2015 | 7.490M |
| March 31, 2015 | 11.64M |
| December 31, 2014 | 17.74M |
| September 30, 2014 | 8.418M |
| June 30, 2014 | 6.392M |
| March 31, 2014 | 5.216M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 91.26M |
| Revolution Medicines, Inc. | 392.47M |
| Moderna, Inc. | 588.00M |
| Intellia Therapeutics, Inc. | 80.50M |
| Denali Therapeutics, Inc. | 97.02M |